Drug Profile
GSK 215083
Alternative Names: GSK-215083Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class 2 ring heterocyclic compounds; Antidementias; Quinolones
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom
- 11 May 2016 Preclinical development is undergoing in Alzheimer's disease in United Kingdom